(Q24241098)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19370615%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

0 references

1 reference

title

HMG CoA reductase inhibitors (statins) for kidney transplant recipients (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19370615%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19370615%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

David Johnson

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19370615%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

Jonathan Craig

series ordinal

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19370615%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

Giovanni Strippoli

series ordinal

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19370615%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

1

Sankar D Navaneethan

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19370615%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

4

Sagar U Nigwekar

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19370615%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

publication date

15 April 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19370615%20AND%20SRC:MED&resulttype=core&format=json

Cochrane Database of Systematic Reviews

26 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19370615%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19370615%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

page(s)

CD005019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19370615%20AND%20SRC:MED&resulttype=core&format=json

Risk factors for reaching renal endpoints in the assessment of Lescol in renal transplantation (ALERT) trial

26 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005019.PUB3

Renal dysfunction is a strong and independent risk factor for mortality and cardiovascular complications in renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005019.PUB3

Long-term cardiac outcomes in renal transplant recipients receiving fluvastatin: the ALERT extension study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005019.PUB3

Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005019.PUB3

Beneficial effect of early initiation of lipid-lowering therapy following renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005019.PUB3

Cardiovascular risk and renal transplantation: post hoc analyses of the Assessment of Lescol in Renal Transplantation (ALERT) Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005019.PUB3

fluvastatin prevents cardiac death and myocardial infarction in renal transplant recipients: post-hoc subgroup analyses of the ALERT Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005019.PUB3

Gender-associated risk factors for cardiac end points and total mortality after renal transplantation: post hoc analysis of the ALERT study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005019.PUB3

Effect of pravastatin treatment on the evolution of extracoronary atherosclerosis in renal transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005019.PUB3

Pravastatin improves low-density lipoprotein oxidation in renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005019.PUB3

The effects of lipid-lowering agents on acute renal allograft rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005019.PUB3

The effect of pravastatin on acute rejection after kidney transplantation--a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005019.PUB3

Effect of a 3-year therapy with the 3-hydroxy-3-methylglutaryl coenzyme a reductase-inhibitor fluvastatin on endothelial function and distensibility of large arteries in hypercholesterolemic renal transplant recipient

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005019.PUB3

Efficacy and drug interactions of the new HMG-CoA reductase inhibitors cerivastatin and atorvastatin in CsA-treated renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005019.PUB3

Effect of lovastatin, an HMG CoA reductase inhibitor, on acute renal allograft rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005019.PUB3

Safety and efficacy of simvastatin for hyperlipidemia in renal transplant recipients: a double-blind, randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005019.PUB3

First United Kingdom Heart and Renal Protection (UK-HARP-I) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005019.PUB3

Cardiovascular risk factors and diseases after renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005019.PUB3

Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005019.PUB3

Fluvastatin reduces atherogenic lipids without any effect on native endothelial function early after kidney transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005019.PUB3

Lipoprotein patterns in renal transplant patients: a comparison between FK 506 and cyclosporine A patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005019.PUB3

Patient survival after renal transplantation III: the effects of statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005019.PUB3

Effect of fluvastatin on renal end points in the Assessment of Lescol in Renal Transplant (ALERT) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005019.PUB3

Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005019.PUB3

Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005019.PUB3

Effect of fluvastatin on endothelium-dependent brachial artery vasodilation in patients after renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005019.PUB3

MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005019.PUB3

Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: a report from the Managing Dyslipidemias in Chronic Kidney Disease Work Group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005019.PUB3

Statin use after renal transplantation: a systematic quality review of trial-based evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005019.PUB3

Inhibition of the mevalonate pathway: benefits beyond cholesterol reduction?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005019.PUB3

Hyperlipidemia and cardiovascular disease after organ transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005019.PUB3

Metaanalysis of statins and survival in de novo cardiac transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005019.PUB3

Incidence of new-onset hypercholesterolemia in renal transplant patients treated with FK506 or cyclosporine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005019.PUB3

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre ra

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005019.PUB3

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005019.PUB3

HMG CoA reductase inhibitors (statins) for kidney transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005019.PUB3

No detrimental effect on renal function during long-term use of fluvastatin in renal transplant recipients in the Assessment of Lescol in Renal Transplantation (ALERT) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005019.PUB3

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005019.PUB3

Genetic analysis of fluvastatin response and dyslipidemia in renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005019.PUB3

Relationship between mevalonate pathway and arterial myocyte proliferation: in vitro studies with inhibitors of HMG-CoA reductase

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005019.PUB3

7 January 2021

Effects of different inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, pravastatin sodium and simvastatin, on sterol synthesis and immunological functions in human lymphocytes in vitro

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005019.PUB3

7 January 2021

Effects of nicotinic acid and lovastatin in renal transplant patients: a prospective, randomized, open-labeled crossover trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005019.PUB3

7 January 2021

Comparison of the effects of simvastatin and pravastatin on acute rejection episodes in renal transplant patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005019.PUB3

7 January 2021

A double-blind placebo controlled trial of simvastatin for the treatment of dyslipidaemia in renal allograft recipients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005019.PUB3

7 January 2021

Effect of fluvastatin on acute renal allograft rejection: a randomized multicenter trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005019.PUB3

7 January 2021

Therapy of post-renal transplantation hyperlipidaemia: comparative study with simvastatin and fish oil

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005019.PUB3

7 January 2021

Cardiovascular morbidity and risk factors in renal transplant patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005019.PUB3

7 January 2021

Adverse effect of cyclosporin on plasma cholesterol in renal transplant recipients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005019.PUB3

7 January 2021

Lipid abnormalities in cyclosporine-prednisone-treated renal transplant recipients.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005019.PUB3

7 January 2021

Risk factors predicting chronic rejection of renal allografts

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005019.PUB3

7 January 2021

Low-dose simvastatin is a well-tolerated and efficacious cholesterol-lowering agent in ciclosporin-treated kidney transplant recipients: double-blind, randomized, placebo-controlled study in 40 patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005019.PUB3

7 January 2021

10.1002/14651858.CD005019.PUB3

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19370615%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

1 reference